Multiple Myeloma Drug Combination Improves Overall Survival


Addition of bortezomib to lenalidomide and low-dose dexamethasone therapy extends disease control.

A triple drug combination significantly improved disease control in the treatment of multiple myeloma during a recent clinical trial.

Adding bortezomib to the current standard of care in multiple myeloma of lenalidomide (Revlimid) and low-dose dexamethasone (RVd) significantly improved progression-free survival (PFS) versus lenalidomide and low-dose dexamethasone (Rd) in newly-diagnosed patients.

Data from the phase 3 study was presented at the 57th American Society of Hematology Annual Meeting.

Revlimid was previously approved in combination with dexamethasone to treat multiple myeloma, and in combination with dexamethasone for patients with multiple myeloma who received at least 1 prior therapy.

Revlimid was also previously approved for patients with mantle cell lymphoma whose disease relapsed or progressed after 2 prior therapies, 1 of which included bortezomib.

The phase 3 trial included 471 patients administered RVd, who achieved a median PFS of 43 months compared with a median PFS of 30 months in patients receiving Rd monotherapy [HR = 0.712, 96% CI, one-sided p=0.0018 (two-sided p=0.0037)].

Furthermore, patients administered RVd had a median overall survival (OS) of 75 months compared with a median of 64 months in patients administered Rd [HR=0.709, 96% CI, one-sided p=0.0125 (two-sided p=0.250)].

In terms of safety, grade 3 or higher adverse events by common toxicity criteria in patients receiving RVd versus Rd, respectively, included neurologic (33% vs. 11%), pain (12% vs. 4%), sensory (23% vs. 3%), and gastrointestinal (22% vs. 8%) events, according to Celgene, the manufacturer of Revlimid.

"This study is a great example of how new combinations are building on the backbone of myeloma research with Revlimid and low-dose dexamethasone," said Markus Renschler, MD, senior vice president and global head of Hematology & Oncology Medical Affairs for Celgene. "The study demonstrated that adding bortezomib to standard care Revlimid and dexamethasone improved remission rates and extended the duration of disease control."

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder -
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff -
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk -
Capsules medicine and white medicine bottles on table | Image Credit: Satawat -
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn -
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl -
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka -
Bottle and scattered pills on color background, top view | Image Credit: New Africa -
pharmacy | Image Credit: Diego Cervo -
© 2024 MJH Life Sciences

All rights reserved.